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Abstract: Fatty liver is commonly associated with alcohol inges-
tion and abuse. While the molecular pathogenesis of these fatty
changes is well understood, the histochemical and pharmacological
mechanisms by which ethanol stimulates these molecular changes
remain unknown. During ethanol metabolism, adenosine is gener-
ated by the enzyme ecto-50-nucleotidase, and adenosine production
and adenosine receptor activation are known to play critical roles
in the development of hepatic ﬁbrosis. We therefore investigated
whether adenosine and its receptors play a role in the development
of alcohol-induced fatty liver. WT mice fed ethanol on the Lieber–
DeCarli diet developed hepatic steatosis, including increased hepatic
triglyceride content, while mice lacking ecto-5-nucleotidase or aden-
osine A1 or A2B receptors were protected from developing fatty liver.
Similar protection was also seen in WT mice treated with either an
adenosine A1 or A2B receptor antagonist. Steatotic livers demon-
strated increased expression of genes involved in fatty acid synthesis,
which was prevented by blockade of adenosine A1 receptors, and
decreased expression of genes involved in fatty acid metabolism,
which was prevented by blockade of adenosine A2B receptors. In
vitro studies supported roles for adenosine A1 receptors in promoting
fatty acid synthesis and for A2B receptors in decreasing fatty acid
metabolism. These results indicate that adenosine generated by eth-
anol metabolism plays an important role in ethanol-induced hepatic
steatosis via both A1 and A2B receptors and suggest that targeting
adenosine receptors may be effective in the prevention of alcohol-
induced fatty liver.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Journal of Hepatology 20
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patients with fatty liver and other chronic liver diseases [1].
In this manuscript and prior studies, Peng et al. [2,3], note that
heightened extracellular adenosine levels, induced as a result of
ethanol or fructose metabolism via interactions with two of the
type-1 (P1)-adenosinergic receptors, signiﬁcantly contribute to
ethanol-induced fatty liver disease. Adenosine and other puriner-
gic mediator effects on the liver are closely regulated by cell sur-
face ectonucleotidases (i.e., ecto-AMPase/CD73, ecto-ADPases
and ecto-ATPases, mainly CD39). These ecto-enzymes hydrolyze
extracellular nucleotides in a tandem manner, ultimately gener-
ating adenosine [4]. Extracellular nucleotides are considered a
major source of adenosine while membrane transporters that
serve as scavengers also regulate concentrations of these media-
tors [5]. Adenosine often exerts opposing effects to extracellular
nucleotides (ATP, ADP, UTP, and UDP) that bind type-2 puriner-
gic/pyrimidinergic (P2Y G-protein coupled) receptors and P2X
ATP-gated cation channels. Adenosine and extracellular nucleo-
tides are recognized by a variety of P1-adenosine and P2-recep-
tors on hepatocytes, platelets, endothelium, and vascular
smooth muscle, hepatic stellate and immune cells (reviewed in
[4]). Thus, all hepatic cells express components of the purinergic
signaling apparatus that could impact metabolic and associated
inﬂammatory responses, including glucose release, protein and
glutathione synthesis, hepatic regulation of renal Na+/water
excretion, and portal blood ﬂow [4,6].
Here, mice were fed an alcohol containing Lieber–DeCarli
liquid diet to investigate whether ethanol-induced adenosine
release stimulates hepatic steatosis. The underlying mechanisms
were then studied. The development of fatty liver was almost
completely blocked by adenosine A1 or A2B receptor antagonists.
Further evidence was derived from studies using mice deﬁcient
in either of these adenosine receptors or ecto-50-nucleotidase
that were protected from alcohol-induced hepatic steatosis.
In the liver, as in other tissues, ethanol (or fructose) ingestion
interfered with adenosine uptake and also resulted in an ecto-
enzyme dependent increase in adenosine concentrations
together with mRNA for the A1, A2B, and A2A receptors. Adeno-
sine was further shown to impact expression of key enzymes in
lipid metabolism, and thereby promotes hepatic steatosis.
Chronic ethanol ingestion increased mRNA levels of SREBP1 and
PPARc, and downstream expression of ACL, and FAS in livers from
WT, A2B null, and enprofylline (A2B receptor antagonist) treated
mice. In parallel, adenosine A1 receptor deletion or blockade
using DPCPX prevented the ethanol-induced increase in expres-
sion of these genes. In contrast, ethanol ingestion reduced mRNA10 vol. 52 j 941–943
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expression of PPARa, CPTL, and ACCA in the livers of WT, A1 null,
and DPCPX-treated mice, while blockade or deletion of A2B
receptors abrogated these ethanol-induced decreases. Alcohol
ingestion was also shown to diminish AMP-kinase (AMPK) phos-
phorylation in mouse liver, an effect shown to be A2B receptor-
dependent.
Studies carried out in vitro on a hepatocytic cell line provided
additional mechanistic data. Adenosine A1 receptor activation
stimulated SREBP1 translocation to the nucleus, thereby promot-
ing fatty acid synthesis and accumulation, whereas A2B receptor
activation diminished phosphorylation and activation of AMPK
and downregulated nuclear PPARa, thereby inhibiting fatty acid
utilization and transport. The net result of increased fatty acid
synthesis and diminished utilization clearly explain the patho-
genesis of steatosis in alcoholic (and likely non-alcoholic) hepatic
steatosis (Fig. 1).
Furthermore, adenosine, acting via A2A receptors, is already
known to promote hepatic ﬁbrosis in response to toxins like
thioacetamide and carbon tetrachloride [3,7]. Somewhat dualisti-
cally, adenosine stimulates the ﬁbrogenic potential of hepatic
stellate cells, the major producers of the ﬁbrotic extracellular
matrix, by upregulating the production of procollagen I, and ﬁbr-Ethanol
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Fig. 1. Scheme depicting the possible role of ectonucleotidases and purinergic r
Extracellular nucleotides (chieﬂy di- and tri-phosphate nucleosides) bind type-2 purinerg
and Th17 cells. These purinergic mediators are scavenged and converted to adenosine vi
ethanol or fructose, excess extracellular adenosine seems to be generated by the liver
dependent manner. Adenosine binds to several type 1 purinergic receptors to often ex
involved in fatty acid synthesis are upregulated and those involved in lipid degradation a
in turn induces hepatic steatosis. Furthermore, chronic exposure of hepatic stellate c
Adenosine has other effects in that this nucleoside dampens acute inﬂammatory respon
immunosuppressive properties of regulatory T cells (Treg). NO, nitric oxide; M/, macro
942 Journal of Hepatology 201ogenic growth factors such as CTGF and TGF-b but also provides a
proliferative ‘‘stop” signal to these activated cells [8,9]. Many of
the effects of methotrexate, known to cause hepatic and pulmon-
ary ﬁbrosis, may be associated with enhanced release of adeno-
sine [10].
These data further suggest that adenosine receptor antago-
nism may provide a novel approach for the treatment and pre-
vention of alcoholic and, possibly, non-alcoholic fatty liver
disease. Interestingly, chronic use of caffeine, a nonselective
adenosine receptor antagonist, has been associated with
decreased hepatic ﬁbrosis [11].
The major ectonucleotidases expressed by hepatic vascular
endothelium, vascular pericytes, and leukocytes belong to the
CD39 family, or are alkaline phosphatases and ecto-50-nucleoti-
dases such as CD73 [4]. Livers from CD73-deﬁcient mice fed eth-
anol or fructose release signiﬁcantly less adenosine than wild
type mice and are partly protected from developing fatty liver
disease and toxin-induced hepatic ﬁbrosis [2,3,7]. Of note,
CD39, which is upstream of ecto-50-nucleotidase/CD73 in the
ultimate generation of adenosine, has important effects in
promoting experimental pancreatic ﬁbrosis [12] and impacting
liver ﬁbrosis (unpublished observations).CD39
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eceptors in the evolution of hepatic steatosis, inﬂammation, and ﬁbrosis.
ic receptors on vascular cells, platelets, and immune cells to induce T helper (Th)1
a the actions of CD39 and CD73 ectonucleotidases. Following chronic exposure to
from AMP (the product of CD39 phosphohydrolysis of NTP and NDP) in a CD73-
ert opposing effects to those seen with extracellular nucleotides. Liver enzymes
re downregulated via signaling through A1 and A2B receptors, respectively, which
ells/myoﬁbroblasts to adenosine drives ﬁbrogenic activation via A2A receptors.
ses in endothelial cells or macrophages via A2A receptors and is responsible for
phage. For the other abbreviations refer to the text.
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In contrast to these deleterious manifestations associated
with adenosine as shown here, vascular CD39, CD73, and soluble
adenosine have salutary effects in dampening acute inﬂamma-
tion, immune responses, and in limiting vascular injury and
platelet activation seen in the setting of organ ischemia and
reperfusion [4,13]. As noted above, Peng et al. also suggest that
their ﬁndings may be applicable to forms of non-alcoholic hepatic
steatosis and steatohepatitis (NASH), as linked with diabetes and
hyperlipidemia. Curiously, it is known that deletion of CD39 (that
would limit adenosine formation) results in insulin resistance
[14], with several features of the metabolic syndrome and a ten-
dency towards heightened vascular inﬂammation.
How such divergent beneﬁcial and deleterious effects are
mediated over time and at different tissue sites remains currently
unclear. It is feasible that experimental outcomes may be quite
different when tissues are exposed to rapid, acute vs. slow,
chronic increases in extracellular levels of nucleotides and the
resulting nucleoside ﬂuxes.
A possible take home message is that adenosine can be pro-
tective in the acute inﬂammatory setting but also participates
in a ﬁnal common pathway leading to development of hepatic
steatosis, ﬁbrosis, and ultimately to cirrhosis. Some of the diver-
gent elements of the purinergic response are susceptible to inter-
vention, especially with the availability of speciﬁc receptor
antagonists. These pharmacological tools and animal models will
permit us to determine how the temporospatial effects of adeno-
sine are regulated in liver diseases and likely lead to novel tar-
geted therapies.Conﬂicts of interest
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